8 research outputs found
<span style="font-size:11.0pt;font-family: "Times New Roman";mso-fareast-font-family:"Times New Roman";mso-bidi-font-family: Mangal;mso-ansi-language:EN-GB;mso-fareast-language:EN-US;mso-bidi-language: HI" lang="EN-GB">Virtual screening and docking exploration on estrogen receptor: An <i>in silico</i> approach to decipher novel anticancer agents</span>
389-395Breast cancer
is a prominent disorder that affects mostly mid aged women with a high
intensity, upsetting every ninth women of ten. The available drugs and
treatments fall back as they do not completely eradicate the cancerous cells
from body. Hence, newer and more effective drugs and treatments against breast
cancer are the need-of-hour. The increased level of estrogen within body
increases the chance of breast cancer, whereas the regular concentration plays
significant role in normal cell functioning. Melatonin is popularly used as an anti-estrogenic
compound, whereas violacein an active secondary metabolite secreted by bacteria
like ‘Chromobacterium violaceum’
has strong structural similarity with melatonin and, thus, possess latency of
being tested for its anti-cancerous activity. In the current study, docking and
virtual screening was utilized to prove the fact that violacein and similar
compounds can bind more efficiently to estrogen receptor than that of melatonin
and, hence, has potential to emerge as lead anti-estrogenic compound in
treatment of breast cancer.
</span